Evaluating Efficacy and Quality-of-Life Impacts Seen in OASIS-4

OASIS-4 (NCT05587296) is the pivotal phase 3, randomized, placebo-controlled trial that evaluated elinzanetant (Lynkuet) in patients with vasomotor symptoms (VMS) attributable to endocrine therapy for breast cancer or ductal carcinoma in situ. Carmine Valenza, MD, MPH, PhD(c), describes the trial design: 474 patients with at least 35 moderate-to-severe VMS per week were enrolled and randomized to receive elinzanetant or placebo for 12 weeks, after which placebo recipients crossed over to active therapy for an additional 40 weeks, for a total study duration of 52 weeks. Co-primary end points were the mean change in daily VMS frequency at 4 weeks and at 12 weeks compared with placebo.

At baseline, patients reported a mean of 11 VMS per day—a substantial symptom burden with documented impact on quality of life and treatment adherence. At the 4-week primary landmark, elinzanetant-treated patients experienced approximately 6 fewer VMS per day compared with 3 fewer in the placebo arm; this benefit was maintained at week 12. Valenza highlights the early onset of effect as clinically meaningful: Even at 1 week of treatment, elinzanetant produced greater reductions than placebo despite the well-recognized placebo effect observed in VMS trials. Across subgroups, approximately 75% of patients treated with elinzanetant achieved a reduction in daily VMS frequency of more than 50% by week 12.

The quality-of-life data from OASIS-4 reinforce the clinical value of VMS control in this population. Using the Menopause-Specific Quality of Life questionnaire—which evaluates vasomotor, psychosocial, physical, and sexual domains—Valenza notes that the most pronounced improvement was observed in the vasomotor domain, as expected, but that clinically meaningful gains were also recorded across all other domains. This finding indicates that the benefits of elinzanetant extend beyond symptom frequency reduction to encompass broader aspects of patient well-being. A published network meta-analysis further contextualizes these results, demonstrating that NK receptor inhibitors achieve efficacy comparable to MHT and superior to other nonhormonal options, including gabapentin and SSRIs, in patients without a prior breast cancer diagnosis.